AVA-6000

5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below. Presentation details Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumorsSession Title: First-in-Human Phase I Clinical Trials 2Session Date and Time: Tuesday 9 April 2024 9:00 AM - 12:30 PMLocation: San Diego Convention Center, San Diego CA USAAbstract Presentation Number: CT188First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust -Ends- For further information from Avacta Group plc, please contact: Avacta Group plcAlastair Smith, Chief Executive OfficerTony Gardiner, Chief Financial OfficerMichael Vinegrad, Group Communications DirectorTel: +44 (0) 1904 21 7070www.avacta.comStifel Nicolaus Europe Limited (Nomad and Joint Broker)Nicholas Moore / Nick Adams / Samira Essebiyea / Nick HarlandTel: +44 (0) 207 710 7600www.stifel.comPeel Hunt (Joint Broker)James Steel / Chris Golden / Patrick BirkholmTel: +44 (0) 207 418 8900www.peelhunt.com ICR Consilium (Media and IR)Mary-Jane Elliott / Jessica Hodgson / Sukaina Virjiavacta@consilium-comms.com About AVA6000AVA6000, Avacta Therapeutics’ lead oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment (TME). FAP is selectively overexpressed in many solid tumors. The peptide moiety (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin directly to the TME. About Avacta Group plc - https://www.avacta.comAvacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division focused on supporting healthcare professionals and broadening access to testing. Avacta’s two proprietary platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets. The pre|CISION™ platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a “precision medicine”. The lead pre|CISION™ programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity. Affimer® is a novel biologic platform which has significant technical and commercial advantages compared with antibodies and is used both to develop advanced immunotherapies and to improve the performance of immunodiagnostics. With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit. To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/

19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical progress Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division. Simon has over 26 years’ commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America. Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:“As Chief Business Officer, Simon will work closely with the senior management team and lead commercial strategy and business development activities at this exciting period in the Company’s development as compelling clinical data emerges from the AVA6000 phase 1 trial. “These emerging data give us, for the first time, the opportunity to accelerate ongoing discussions as well as to generate new opportunities through our business development activities aimed at delivering licensing opportunities for the pre|CISIONTM and Affimer® platforms.” Simon’s career began at University of Oxford spin-out, Oxagen Limited where he established and built a franchise in Women’s Health, initially as Programme Director and later as Director of Business Development. He subsequently joined next generation sequencing company Solexa where, as Business Development Director, he was responsible for all commercial activities and external communications leading up to the reverse takeover of Nasdaq-listed Lynx Therapeutics to form Solexa Inc. which was later acquired by Illumina. Since then, Simon has worked as a consultant providing expert commercial and business development resources to a wide range of biopharmaceutical companies. Prior to moving into industry, Simon was a Wellcome Trust Research Fellow at the University of Oxford and an Honorary Clinical Lecturer at Imperial College London. He has published widely, particularly in the field of complex disease genetics. Dr Simon Bennett, Chief Business Officer, Avacta Therapeutics commented:“Avacta is at a pivotal point, having recently announced clinical data that have already begun to generate interest from potential commercial partners. I am delighted to be joining at such an exciting point in the journey of the business, to help the team optimise the commercial opportunities of their technologies and assets.” -Ends- For further information from Avacta Group plc, please contact: Avacta Group plcAlastair Smith, Chief Executive OfficerTony Gardiner, Chief Financial OfficerMichael Vinegrad, Group Communications DirectorTel: +44 (0) 1904 21 7070www.avacta.comStifel Nicolaus Europe Limited (Nomad and Joint Broker)Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / William Palmer-BrownTel: +44 (0) 207 710 7600www.stifel.comPeel Hunt (Joint Broker)James Steel / Chris Golden / Patrick BirkholmTel: +44 (0) 207 418 8900www.peelhunt.com ICR Consilium (Media and IR)Mary-Jane Elliott / Jessica Hodgson / Sukaina Virjiavacta@consilium-comms.com About Avacta Group plc - https://www.avacta.com Avacta Group is a UK-based company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division, which is executing on an M&A led growth strategy to create a full-spectrum diagnostics business focused on supporting healthcare professionals and broadening access to testing. Avacta’s two proprietary platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets. The pre|CISION™ platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a “precision medicine”. The lead pre|CISION™ programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity. Affimer® is a novel biologic platform which has significant technical and commercial advantages compared with antibodies and is used both to develop advanced immunotherapies and to improve the performance of immunodiagnostics. With a balanced business and capital allocation model: a high-value oncology pipeline supported by a revenue generating, fast-growing diagnostics business, Avacta seeks to create long-term shareholder value alongside patient benefit. To register for news alerts by email go to https://avacta.com/investors/investor-news-email-alerts/